Ibritumomab Tiuxetan and High-Dose Melphalan as Conditioning Regimen Before Autologous Stem Cell Transplantation for Elderly Patients With Lymphoma in Relapse or Resistant to Chemotherapy. A Multicenter Phase I Trial.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Melphalan (Primary) ; Rituximab; Vinorelbine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 15 May 2019 Biomarkers information updated
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.